Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-77242113 in Moderate to Severe Plaque Psoriasis
NCT06143878Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2024
- Primary completion
- Sep 2024
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of icotrokinra in plaque psoriasis (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Investigator's Global Assessment (IGA) 0 or 1 at 16 weeks and Psoriasis Area and Severity Index (PASI) 90 at 16 weeks. Started Jan 2024; status: active, not recruiting.
02
Drugs
icotrokinra
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06143878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06143878.